FDA agrees to review Takeda and Affymax's anemia drug

07/27/2011 | Xconomy

Affymax and Takeda Pharmaceutical's drug candidate peginesitide was accepted for FDA review. Formerly named Hematide, the once-monthly drug is intended for anemia in kidney patients on dialysis.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care